Hybrigenics

Hybrigenics focuses on advanced protein interaction discovery and synthetic nanobody services, utilizing innovative technologies to support research in fundamental biology and pharmaceutical development. Hybrigenics, founded in 1997 and headquartered in Paris, France, specializes in protein interaction discovery. The company has conducted a total of 11 deals, with the most recent funding round occurring on March 27, 2012, when it raised EUR 3. 3 million from undisclosed investors.

Hybrigenics specializes in advanced protein interaction discovery and synthetic nanobody services, primarily leveraging its proprietary ULTImate yeast two-hybrid (Y2H) screening platform. The company offers solutions for identifying protein-protein interactions, critical for fundamental research, pharmaceutical development, and agro-science applications. Their services include custom nanobody selection through the Hybribody platform, allowing researchers to generate animal-free intrabodies for various applications, including viral protein detection and inhibition. Hybrigenics serves a diverse client base, including academic institutions, biotechnology firms, and pharmaceutical companies engaged in research to address challenges in molecular biology and drug discovery across global markets, including North America, Europe, and Asia.

Hybrigenics operates on a B2B model, providing its services primarily through contractual agreements, project-based engagements, and collaborations with research institutions and companies. Revenue for the most recent year, 2023, amounted to EUR 3,543,160. 80, with an EBITDA of EUR -253,369. 10.

Clients typically engage in specific projects, such as Y2H screening, selecting libraries and bait strategies tailored to their research needs. Revenue is generated from these bespoke service offerings, including the flagship ULTImate Y2H service and the Hybribody platform, with pricing structures based on the scope and complexity of the projects. Hybrigenics plans to leverage funding raised in March 2012, amounting to EUR 3. 3 million, to support its future growth strategies, which include the continued development of new products and expansion into additional geographic markets.

The company is exploring advancements in its nanobody offerings and aims to extend its reach into North America and Asia by 2025.